Monday, August 4, 2025

Latest

Revive Therapeutics To Investigate Novel Oral Dosage Forms Of Psilocybin

Revive Therapeutics (CSE: RVV) has provided an update to the market in regards to its psilocybin-based pharmaceutical program. Revive intends to utilize its patent-pending psilocybin formulations and its exclusive licensed drug delivery technology to investigate novel oral dosage forms of psilocybin, such as in the form of tablets or thin films like breath strips.

It has been found that several parallels exists between Revive’s IP portfolio of psilocybin-based formulations and that of the composites the firm studied with cannabidiol in the past when it comes to drug delivery mechanisms. As a result, Revive intends to research both methods together, as both provide unique qualities such as the potential for time release compositions and rapid on-set. To this end, Revive believes the most ideal delivery method will be that of an oral dissolvable tablet or an oral film strip, commonly referred to as a breath strip.

The firms psilocybin-based formulations have been created to synergistically work with the natural pathways of absorption found in the body. The current formulation development plans intend to pursue clinical studies for indications not currently being evaluated with psilocybin, while using the firms unique delivery platform IP as an advantage. For this, Revive will lean on its patent-pending technology that covers methods of producing psilocybin formulations as well as its extraction and crystallization methodologies.

"We are expanding our psilocybin-based pharmaceutical portfolio with unique oral dosage and drug delivery forms that will target and have the potential to treat diseases and disorders currently not investigated with psychedelic compounds. We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies." Michael Frank, CEO

Revive Therapeutics last traded at $0.14 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

San Dimas: First Majestic Silver’s Sleeper Asset

New Gold Q2 Earnings: Record Free Cash Flow

STLLR Gold: The Tower Gold PEA

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Revive Therapeutics Continues With Phase 3 Clinical Trial For Bucillamine, To File For Emergency Use Authorization

Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its...

Wednesday, December 23, 2020, 09:48:31 AM

Havn Life to Supply Revive Therapeutics With Psychedelic Compounds

This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn...

Tuesday, October 20, 2020, 10:16:16 AM

Revive Closes Psilocin Pharma Acquisition, Releases Psilocybin Patent Details

Revive Therapeutics (CSE: RVV) has completed its previously announced acquisition of Psilocin Pharma Corp, a...

Thursday, March 5, 2020, 02:40:39 PM

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Revive Expands Phase 3 COVID-19 Study To Asia Pacific Region, Canada

Revive Therapeutics (CSE: RVV) announced this morning that it is expanding its phase 3 clinical...

Wednesday, August 19, 2020, 12:34:40 PM